Aerie Pharmaceuticals, Inc. (AERI): Price and Financial Metrics


Aerie Pharmaceuticals, Inc. (AERI): $7.56

0.24 (+3.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AERI POWR Grades


  • AERI scores best on the Growth dimension, with a Growth rank ahead of 90.73% of US stocks.
  • AERI's strongest trending metric is Value; it's been moving up over the last 179 days.
  • AERI ranks lowest in Stability; there it ranks in the 2nd percentile.

AERI Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AERI is -11.2 -- better than merely 1.37% of US stocks.
  • AERI's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 1.8% of US stocks.
  • Revenue growth over the past 12 months for Aerie Pharmaceuticals Inc comes in at 133.51%, a number that bests 93.98% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aerie Pharmaceuticals Inc are FUV, AFIB, RVNC, CLIR, and ACER.
  • AERI's SEC filings can be seen here. And to visit Aerie Pharmaceuticals Inc's official web site, go to www.aeriepharma.com.

AERI Valuation Summary

  • AERI's EV/EBIT ratio is -5.3; this is 118.09% lower than that of the median Healthcare stock.
  • AERI's price/earnings ratio has moved up 7.8 over the prior 96 months.
  • Over the past 96 months, AERI's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for AERI.

Stock Date P/S P/B P/E EV/EBIT
AERI 2021-08-31 7.4 -17.8 -4.2 -5.3
AERI 2021-08-30 7.2 -17.3 -4.1 -5.2
AERI 2021-08-27 7.3 -17.5 -4.2 -5.3
AERI 2021-08-26 7.1 -17.1 -4.1 -5.2
AERI 2021-08-25 7.3 -17.6 -4.2 -5.3
AERI 2021-08-24 7.3 -17.5 -4.2 -5.3

AERI Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 80.67%.
  • The 4 year price growth rate now stands at -8.95%.
  • Its 2 year net cashflow from operations growth rate is now at -31.52%.
Over the past 52 months, AERI's revenue has gone up $194,134,000.

The table below shows AERI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 194.134 -99.154 -74.81
2021-09-30 104.151 -46.682 -166.48
2021-06-30 94.919 -50.191 -166.437
2021-03-31 85.767 -52.922 -175.936
2020-12-31 83.138 -64.69 -183.101
2020-09-30 83.112 -114.176 -192.028

AERI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AERI has a Quality Grade of C, ranking ahead of 68.87% of graded US stocks.
  • AERI's asset turnover comes in at 0.255 -- ranking 175th of 682 Pharmaceutical Products stocks.
  • UTHR, AMGN, and AMRN are the stocks whose asset turnover ratios are most correlated with AERI.

The table below shows AERI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.255 0.739 -0.424
2021-03-31 0.226 0.698 -0.460
2020-12-31 0.212 0.695 -0.470
2020-09-30 0.206 0.754 -0.488
2020-06-30 0.189 0.790 -0.516
2020-03-31 0.201 0.867 -0.627

AERI Price Target

For more insight on analysts targets of AERI, see our AERI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.27 Average Broker Recommendation 1.5 (Moderate Buy)

AERI Stock Price Chart Interactive Chart >

Price chart for AERI

AERI Price/Volume Stats

Current price $7.56 52-week high $19.26
Prev. close $7.32 52-week low $4.81
Day low $7.19 Volume 1,366,200
Day high $7.69 Avg. volume 788,620
50-day MA $6.78 Dividend yield N/A
200-day MA $8.82 Market Cap 367.59M

Aerie Pharmaceuticals, Inc. (AERI) Company Bio


Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company was founded in 2005 and is based in Irvine, California.


AERI Latest News Stream


Event/Time News Detail
Loading, please wait...

AERI Latest Social Stream


Loading social stream, please wait...

View Full AERI Social Stream

Latest AERI News From Around the Web

Below are the latest news stories about Aerie Pharmaceuticals Inc that investors may wish to consider to help them evaluate AERI as an investment opportunity.

Aerie Pharmaceuticals, Inc. (AERI) CEO Raj Kannan on Q4 2021 Results - Earnings Call Transcript

Aerie Pharmaceuticals, Inc. (AERI) Q4 2021 Earnings Conference Call February 24, 2022, 17:00 ET Company Participants Hans Vitzthum - LifeSci Advisors Raj Kannan - CEO & Director Michelle Senchyna - Head, Clinical Development and Medical Affairs Jeffrey Calabrese - Director, Accounting Conference Call Participants François Brisebois - Oppenheimer Louise Chen...

SA Transcripts on Seeking Alpha | February 25, 2022

Aerie Pharmaceuticals Non-GAAP EPS of $1.09 beats by $1.77, revenue of $114.7M beats by $83.54M

Aerie Pharmaceuticals press release (NASDAQ:AERI): Q4 Non-GAAP EPS of $1.09 beats by $1.77. Revenue of $114.7M (+364.4% Y/Y) beats by $83.54M. Outlook: Glaucoma franchise net product revenues: target is $130 million to $140 million, up 16% to 25% versus 2021...

Seeking Alpha | February 24, 2022

Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

DURHAM, N.C., February 24, 2022--Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Yahoo | February 24, 2022

Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer

DURHAM, N.C., February 24, 2022--Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer

Yahoo | February 24, 2022

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Yahoo | February 23, 2022

Read More 'AERI' Stories Here

AERI Price Returns

1-mo 39.23%
3-mo -21.41%
6-mo 3.42%
1-year -59.74%
3-year -73.90%
5-year -86.20%
YTD 7.69%
2021 -48.04%
2020 -44.10%
2019 -33.05%
2018 -39.58%
2017 57.86%

Continue Researching AERI

Want to see what other sources are saying about Aerie Pharmaceuticals Inc's financials and stock price? Try the links below:

Aerie Pharmaceuticals Inc (AERI) Stock Price | Nasdaq
Aerie Pharmaceuticals Inc (AERI) Stock Quote, History and News - Yahoo Finance
Aerie Pharmaceuticals Inc (AERI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5327 seconds.